KRAS Mutations and Precision Oncology: From KRAS G12C Inhibitors to Next-Generation RAS-Targeted Therapies

How KRAS mutation subtypes shape targeted treatment, from approved KRAS G12C inhibitors in China to investigational RAS(ON) inhibitors such as daraxonrasib.

Top Stories

Global First-in-Class Drug Approved in China: Vosoritide Brings Disease-Modifying Treatment to Children with Achondroplasia

Complete Guide to Lung Cancer Treatment in China: Costs, Leading Hospitals, and What International Patients Should Know

Latest Coverage

Atopic Dermatitis Welcomes an Important New Treatment: China Approves Ruxolitinib Phosphate Cream for Children Aged 2 and Older and Adults
For patients living with atopic dermatitis (AD), the burden of the disease goes beyond redness, dry skin, and rashes....

What Is the Difference Between Acute and Chronic Leukemia? DengYue RX Explains Leukemia Types and Pharmaceutical Supply
Leukemia is a group of malignant blood disorders that affect the blood-forming tissues and is not a single disease. A...

Rituximab Procurement Options: Different Budget Solutions from Originator Drugs to Biosimilars
In the field of hematologic oncology, Rituximab is a classic targeted biologic with a long history of clinical use. S...

How to Submit a Medicine Request? A Guide to DengYue Pharmacy's Online Medicine Request Service
As the internet and digital services continue to become an increasingly important part of healthcare and the pharmace...

NF1-Associated Plexiform Neurofibroma: Treatment Needs and the Latest Advances in Adult Patients
Neurofibromatosis type 1 (NF1) is a genetic disorder that can manifest from childhood, and some patients develop plex...

Oral Medications for Prostate Cancer: How Can Patients Achieve More Structured Home-Based Management?
As prostate cancer treatment continues to evolve, some patients no longer need to rely entirely on treatment administ...

In-Depth Analysis

KRAS Mutations and Precision Oncology: From KRAS G12C Inhibitors to Next-Generation RAS-Targeted Therapies

Global First-in-Class Drug Approved in China: Vosoritide Brings Disease-Modifying Treatment to Children with Achondroplasia

Complete Guide to Lung Cancer Treatment in China: Costs, Leading Hospitals, and What International Patients Should Know

Atopic Dermatitis Welcomes an Important New Treatment: China Approves Ruxolitinib Phosphate Cream for Children Aged 2 and Older and Adults